Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Public ClinicalTrials.gov record NCT03260894. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
Study identification
- NCT ID
- NCT03260894
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2017 (Actual)
- Primary completion
- Aug 22, 2018 (Actual)
- Completion
- Jun 4, 2025 (Actual)
- Last update posted
- May 22, 2026
2017 – 2025
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Oncology Hematology | Scottsdale | Arizona | 85258 | — |
| Scottsdale Healthcare | Scottsdale | Arizona | 85258 | — |
| Arizona Oncology Associates PC- HOPE | Tucson | Arizona | 85711 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| UC Irvine Comprehensive Cancer Center/Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Woodlands Medical Specialists, PA | Pensacola | Florida | 32503 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Atlanta Cancer Care - Conyers | Conyers | Georgia | 30094 | — |
| Northwest Georgia Oncology Centers Pc | Marietta | Georgia | 30060 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Southeast Nebraska Hematology & Oncology Consultants, P.C. | Lincoln | Nebraska | 68510 | — |
| New York Oncology Hematology P.C | Albany | New York | 12208 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| University of Tennessee Erlanger Oncology & Hematology | Chattanooga | Tennessee | 37403 | — |
| The West Clinic, P.C. | Germantown | Tennessee | 38138 | — |
| US Oncology and Research | The Woodlands | Texas | 77380 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| Shenandoah Oncology, P.C. | Winchester | Virginia | 22601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03260894, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2026 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03260894 live on ClinicalTrials.gov.